Review



human recombinant srage  (ProSpec)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ProSpec human recombinant srage
    ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without <t>sRAGE</t> or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Human Recombinant Srage, supplied by ProSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant srage/product/ProSpec
    Average 90 stars, based on 1 article reviews
    human recombinant srage - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways"

    Article Title: DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2018.02824

    ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without sRAGE or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Figure Legend Snippet: ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without sRAGE or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Techniques Used: Incubation, Control, Expressing, Transfection, Gene Expression

    (A) Biacore T200 analysis of DWEYS inhibition of HMGB1-RAGE binding. sRAGE was immobilized on a CM5 sensor chip, HMGB1 with or without varying concentrations of DWEYS were added as analytes. IC50 was 34.7 μM. (B) Inhibition curve used for IC50 evaluation as noted in the methods section. (C,D) Human monocytes were incubated with labeled HMGB1 (red) alone ( C , top panel) or HMGB1 and DWEYS ( C , middle panel) or HMGB1 and control peptide ( C , bottom panel) for 20 min. Cells were counterstained with DAPI and imaged using a confocal laser scanning microscope. (D) Indicates adjusted fluorescence intensity for three experiments. (E) Primary human monocytes were incubated with HMGB1 and with or without DWEYS or control peptide for 4 h. lSG expression was evaluated using qPCR. Results indicate mean ± SD of three independent experiments. * p < 0.05.
    Figure Legend Snippet: (A) Biacore T200 analysis of DWEYS inhibition of HMGB1-RAGE binding. sRAGE was immobilized on a CM5 sensor chip, HMGB1 with or without varying concentrations of DWEYS were added as analytes. IC50 was 34.7 μM. (B) Inhibition curve used for IC50 evaluation as noted in the methods section. (C,D) Human monocytes were incubated with labeled HMGB1 (red) alone ( C , top panel) or HMGB1 and DWEYS ( C , middle panel) or HMGB1 and control peptide ( C , bottom panel) for 20 min. Cells were counterstained with DAPI and imaged using a confocal laser scanning microscope. (D) Indicates adjusted fluorescence intensity for three experiments. (E) Primary human monocytes were incubated with HMGB1 and with or without DWEYS or control peptide for 4 h. lSG expression was evaluated using qPCR. Results indicate mean ± SD of three independent experiments. * p < 0.05.

    Techniques Used: Inhibition, Binding Assay, Incubation, Labeling, Control, Laser-Scanning Microscopy, Fluorescence, Expressing



    Similar Products

    human recombinant srage  (Sino Biological)
    93
    Sino Biological human recombinant srage
    Human Recombinant Srage, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant srage/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    human recombinant srage - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    intravenous treatment with srage  (R&D Systems)
    93
    R&D Systems intravenous treatment with srage
    Intravenous Treatment With Srage, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/intravenous treatment with srage/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    intravenous treatment with srage - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    recombinant human srage  (R&D Systems)
    90
    R&D Systems recombinant human srage
    Recombinant Human Srage, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human srage/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    recombinant human srage - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    recombinant human srage  (Novoprotein)
    90
    Novoprotein recombinant human srage
    Recombinant Human Srage, supplied by Novoprotein, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human srage/product/Novoprotein
    Average 90 stars, based on 1 article reviews
    recombinant human srage - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    human recombinant srage  (ProSpec)
    90
    ProSpec human recombinant srage
    ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without <t>sRAGE</t> or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Human Recombinant Srage, supplied by ProSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant srage/product/ProSpec
    Average 90 stars, based on 1 article reviews
    human recombinant srage - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    np 001127 human srage fc  (R&D Systems)
    93
    R&D Systems np 001127 human srage fc
    ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without <t>sRAGE</t> or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Np 001127 Human Srage Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/np 001127 human srage fc/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    np 001127 human srage fc - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    human srage fc  (R&D Systems)
    93
    R&D Systems human srage fc
    ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without <t>sRAGE</t> or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Human Srage Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human srage fc/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human srage fc - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    fc conjugated srage rhusrage  (R&D Systems)
    93
    R&D Systems fc conjugated srage rhusrage
    ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without <t>sRAGE</t> or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Fc Conjugated Srage Rhusrage, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fc conjugated srage rhusrage/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    fc conjugated srage rhusrage - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without sRAGE or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Journal: Frontiers in Immunology

    Article Title: DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways

    doi: 10.3389/fimmu.2018.02824

    Figure Lengend Snippet: ISG induction by SLE serum requires either RAGE or FcRlla. (A) Primary human monocytes were incubated with serum from different SLE patients, B2, M91, B31, F72, or control sera, for 4 h. ISG expression was evaluated using qPCR. Data plotted represents fold induction for each gene relative to the sample incubated with control serum and is representative of 30 samples tested. (B) RAGE and FcRlla levels in monocytes treated with RAGE or FcRIIa siRNA, assessed by qPCR. (C) Monocytes were transfected with RAGE, FcRlla, or control siRNA, prior to incubation with SLE serum for 4 h. For each sample (control, RAGE, or FcRlla siRNA transfected cells) fold induction of ISGs was calculated as the ratio of gene expression between treated and untreated cells. (D) Primary human monocytes were treated with SLE serum, with or without sRAGE or monoclonal anti-FcRlla antibody for 4 h. ISG expression was analyzed by qPCR. Results in each case (B–D) indicate mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Article Snippet: Human recombinant sRAGE was purchased from ProSpec (East Brunswick NJ, USA).

    Techniques: Incubation, Control, Expressing, Transfection, Gene Expression

    (A) Biacore T200 analysis of DWEYS inhibition of HMGB1-RAGE binding. sRAGE was immobilized on a CM5 sensor chip, HMGB1 with or without varying concentrations of DWEYS were added as analytes. IC50 was 34.7 μM. (B) Inhibition curve used for IC50 evaluation as noted in the methods section. (C,D) Human monocytes were incubated with labeled HMGB1 (red) alone ( C , top panel) or HMGB1 and DWEYS ( C , middle panel) or HMGB1 and control peptide ( C , bottom panel) for 20 min. Cells were counterstained with DAPI and imaged using a confocal laser scanning microscope. (D) Indicates adjusted fluorescence intensity for three experiments. (E) Primary human monocytes were incubated with HMGB1 and with or without DWEYS or control peptide for 4 h. lSG expression was evaluated using qPCR. Results indicate mean ± SD of three independent experiments. * p < 0.05.

    Journal: Frontiers in Immunology

    Article Title: DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways

    doi: 10.3389/fimmu.2018.02824

    Figure Lengend Snippet: (A) Biacore T200 analysis of DWEYS inhibition of HMGB1-RAGE binding. sRAGE was immobilized on a CM5 sensor chip, HMGB1 with or without varying concentrations of DWEYS were added as analytes. IC50 was 34.7 μM. (B) Inhibition curve used for IC50 evaluation as noted in the methods section. (C,D) Human monocytes were incubated with labeled HMGB1 (red) alone ( C , top panel) or HMGB1 and DWEYS ( C , middle panel) or HMGB1 and control peptide ( C , bottom panel) for 20 min. Cells were counterstained with DAPI and imaged using a confocal laser scanning microscope. (D) Indicates adjusted fluorescence intensity for three experiments. (E) Primary human monocytes were incubated with HMGB1 and with or without DWEYS or control peptide for 4 h. lSG expression was evaluated using qPCR. Results indicate mean ± SD of three independent experiments. * p < 0.05.

    Article Snippet: Human recombinant sRAGE was purchased from ProSpec (East Brunswick NJ, USA).

    Techniques: Inhibition, Binding Assay, Incubation, Labeling, Control, Laser-Scanning Microscopy, Fluorescence, Expressing